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Abstract
Rationale Pharmacological magnetic resonance imaging
(phMRI) provides an approach to study effects of drug chal-
lenges on brain processes. Elucidating mechanisms of drug
action helps us to better understand the workings of neuro-
transmitter systems, map brain function or facilitate drug de-
velopment. phMRI is increasingly used in preclinical research
employing rodent models; however, data interpretation and
integration are complicated by the use of different experimen-
tal approaches between laboratories. In particular, the effects
of different anaesthetic regimes upon neuronal and haemody-
namic processes and baseline physiology could be
problematic.
Objectives This paper investigates how differences in phMRI
research methodologies are manifested and considers associ-
ated implications, placing particular emphasis on choice of
anaesthetic regimes.
Methods A systematic review of rodent phMRI studies was
conducted. Factors such as those describing anaesthetic re-
gimes (e.g. agent, dosage) and parameters relating to physio-
logical maintenance (e.g. ventilatory gases) and MRI method
were recorded.
Results We identified 126 eligible studies and found that the
volatile agents isoflurane (43.7 %) and halothane (33.3 %)
were most commonly used for anaesthesia, but dosage and
mixture of ventilatory gases varied substantially between lab-
oratories. Relevant physiological parameters were usually re-
corded, although 32 % of studies did not provide cardiovas-
cular measures.
Conclusions Anaesthesia and animal preparation can influ-
ence phMRI data profoundly. The variation of anaesthetic
type, dosage regime and ventilatory gases makes consolida-
tion of research findings (e.g. within a specific neurotransmit-
ter system) difficult. Standardisation of a small(er) number of
preclinical phMRI research methodologies and/or increased
consideration of approaches that do not require anaesthesia
is necessary to address these challenges.
Keywords phMRI . Cerebral blood flow . Anesthesia .
Neuroimaging . fMRI . Pharmacological magnetic resonance
imaging . Animal model . Systematic review
Introduction
The application of functional magnetic resonance imaging
(fMRI) techniques to study effects of pharmacological chal-
lenges on brain processes has been termed pharmacological
MRI (phMRI, Leslie and James 2000). This technique relies
on the blood oxygen level dependent (BOLD) contrast mech-
anism to create functional activation maps using the magnetic
susceptibility properties of endogenous deoxyhaemoglobin
(Ogawa et al. 1990). Specifically, areas of neural activity are
associated with an increase in local cerebral blood flow (CBF)
to mee t oxygen demands , g i v i ng a change in
deoxyhaemoglobin levels which is detected by MRI. Impor-
tantly, areas of activation are only indirectly determined by
measuring haemodynamic changes which are assumed to be
coupled to neural activity, including cerebral blood flow, vol-
ume and oxygenation (Logothetis 2008).
Pharmacological MRI usually exploits either the BOLD
technique or alternately MRI measurements of cerebral blood
volume using an administered contrast agent (CBV-MRI) to
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elucidate the workings of neurotransmitter systems and study
mechanisms of drug action on a neurobiological level (Leslie
and James 2000; Honey and Bullmore 2004; Borsook et al.
2006; Martin and Sibson 2008; Minzenberg 2012). It thus
provides a promising approach particularly in neuropharma-
cological research areas such as drug development and testing
(Tracey and Wise 2001; Borsook et al. 2006; Bifone and
Gozzi 2012), and improved MRI system affordability and
accessibility suggest that phMRI will be an increasingly im-
portant method for future research. As such, the potential lim-
itations of phMRI need to be acknowledged. Whilst much
phMRI is conducted in human subjects, the technique is also
increasingly used in preclinical research using animal models.
A significant factor in preclinical phMRI studies is the use of
general anaesthesia in animal studies to avoid movement ar-
tefacts during image acquisition or to prevent suffering when
additional invasive procedures are concurrently introduced,
for instance, to allow multimodal recording (see Steward
et al. (2005)). This can be problematic since the administered
anaesthetic is itself a neuromodulatory agent which affects
basal cerebral haemodynamics, vascular reactivity and/or ce-
rebral metabolism in complex ways (Peeters et al. 2001;
Sicard et al. 2003; Masamoto et al. 2009). Additionally, the
extent to which these factors are affected is agent specific, i.e.
basal values are altered depending on the choice of anaesthet-
ic. Since BOLD signals are necessarily interpreted as a change
relative to baseline, such anaesthetic-induced differences can
ultimately affect the responses to the drug under investigation.
Indeed any parameter changing the animal’s physiological
steady state, e.g. blood pressure (BP), respiratory rate, body
temperature, potentially modulates the haemodynamic phMRI
response to pharmacological challenges (Steward et al. 2005).
Various anaesthetics have been used for phMRI purposes,
with each agent having its advantages and disadvantages.
Alpha-chloralose is popularly used in functional MRI to
achieve robust responses to sensory stimuli as a result of its
minimal effects on CBF, respiration and cerebral glucose me-
tabolism compared to other anaesthetics (Ueki et al. 1992;
Lindauer et al. 1993; Nakao et al. 2001; Austin et al. 2005).
However, the necessity to use a different anaesthetic for in-
duction purposes potentially influences basal physiology in
more complex ways. Urethane is also widely used in preclin-
ical neuroscience research and can be an appropriate choice to
study neurotransmitter systems due to its modest actions on
several receptor types (Maggi and Meli 1986; Hara and Harris
2002). But lowering of heart rate and BP, as well as hyperven-
tilation are disadvantages of urethane, the use of which is also
discouraged due to its carcinogenic nature (Field et al. 1993).
Common volatile anaesthetics including isoflurane and halo-
thane are more suitable choices for longitudinal studies and
additionally have fast induction and recovery rates (Sakai
et al. 2005). However, such volatile agents significantly alter
baseline CBF independent of neural activity (Hendrich et al.
2001; Masamoto et al. 2009). Respiration rate, BP and cere-
bral metabolic rate of oxygen (CMRO2) are depressed in
isoflurane compared to awake conditions (Todd and Drum-
mond 1984; Sicard et al. 2003). Overall, neuroimaging mea-
surements are potentially confounded via complex mecha-
n i s m s o f a c t i o n o f a n a e s t h e t i c s a n d t h e i r
(neuro)physiological effects.
Caution is thus required when interpreting preclinical
phMRI data, where observed signal changes may reflect an
interaction of the effects of the anaesthetic agent and those of
the drug under study. Indeed several studies have presented
differential responses to pharmacological challenge under
varying anaesthetic regimes (Gordon et al. 1995; Gozzi et al.
2008; Du et al. 2009; Liu et al. 2012; Hodkinson et al. 2012).
Intravenous cocaine, for instance, evoked CBF increases in
alpha-chloralose-anaesthetised rats, but reduced CBF under
isoflurane (Du et al. 2009). Similarly, ketamine decreased ac-
tivity in cortical and hippocampal areas under isoflurane,
while alpha-chloralose showed the opposite effect of activa-
tion in the cortex and hippocampus (Hodkinson et al. 2012).
Administration of levo-tetrahydropalmatine (l-THP) showed
least activated areas with isoflurane, most negative activations
with urethane and mixed positive and negative activations
with medetomidine (Liu et al. 2012). In light of these chal-
lenges, this paper will systematically review research method-
ologies used in preclinical phMRI, particularly with respect to
anaesthetic regimes and other physiological maintenance pa-
rameters which are likely to impact upon phMRI signal mea-
surements. The review will be restricted to research involving
rodents, which are by far the most widely used species in this
preclinical field.
Methods
Search strategy
The search for eligible articles was conducted in PubMed and
Web of Science, with the last search carried out on 25th No-
vember 2013. Keywords included “phMRI”, “pharmacologi-
cal MRI”, “pharmacological fMRI”, “pharmacological func-
tional magnetic resonance imaging”, “phfMRI”, “pharmaco-
logical magnetic resonance imaging” and “pharmacologic
MRI”. Using Web of Knowledge, the search strategy was
supplemented by checking references and citations of each
eligible study to identify additional papers. All listed titles
and abstracts were first screened for inclusion criteria, and full
texts of potential articles were then retrieved to evaluate
against eligibility criteria. No restrictions were set on publica-
tion dates, but papers had to be published as full articles in
peer-reviewed journals. Abstracts, poster presentations,
conference proceedings, book chapters, or grey literature
were not searched.
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Inclusion and eligibility criteria
To be considered in this review, studies had to use rodents as
subjects (specifically rats or mice); phMRI studies investigat-
ing humans or animals other than rats or mice were excluded.
The methodology section of each paper was required to pro-
vide details of the anaesthetic regime during the period of data
acquisition, including type and dose of the anaesthetic agent.
Similarly, name and dose of the drug under investigation had
to be stated, and pharmacological challenge needed to occur
under anaesthesia. Given the nature of this review, animals
had to be anaesthetised during data acquisition, with
haemodynamic-based MRI sequences used (e.g. BOLD,
CBV, CBF readouts). Studies were discarded if only anatom-
ical MRI or non-MRI neuroimaging methods (e.g. PET) were
used. A study was considered ineligible if event-related sen-
sory stimulation protocols were used prior to or during phar-
macological challenge (e.g. forepaw stimulation; Kida et al.
2006) but was included when stimulation occurred after
phMRI data were acquired or in a separate experimental
group. Articles were also excluded if the same drug was tested
under several anaesthetic agents or varying doses of anaesthe-
sia (e.g. Liu et al. 2012). Finally, studies which explicitly
stated that pharmacological challenge was applied to purpose-
ly change basal physiological state were excluded (e.g. nor-
epinephrine for hypertension; Wang et al. 2006).
Data recording
Factors of interest for this review were identified prior to
searching for eligible studies. These included information on
citation (author, date, journal), subjects (strain, sex, weight,
number of animals), surgical preparation (tracheotomy/intuba-
tion for mechanical ventilation, blood gases, if applicable),
anaesthetic regime during induction and maintenance (agent,
dose, additional gases if applicable), physiological measure-
ments (body temperature, BP, heart rate), pharmacological
challenge (drug type, dose, targeted molecular and/or neuro-
transmitter system if stated) and phMRI method.
Results
We identified 126 eligible studies for review, and a complete
list of reviewed papers is included in the Supplementary Ref-
erences. A summary of the details of each included study is
shown in Table S1. Most studies investigated rats (92.1 %),
with the most common strain being Sprague–Dawley rats
(57.9 %), while 7.9 % used mice as subjects. The use of male
rodents was alsomore prevalent (81.7%) than females (4.8%;
12.7 % not reported, 0.8 % used both males and females). Ten
studies (7.9 %) reported both the age and the weight of
animals in the study, 68.3 % reported weight alone and
6.3% reported age alone; 17.5% of studies gave no indication
of animal age or weight. A list of journals in which papers
were published is presented in Table S2.
Anaesthetic regime for induction
For induction purposes, the volatile agent isoflurane was the
most commonly employed anaesthetic agent (49.2%), follow-
ed by halothane (37.3.2 %; see Fig. 1). Urethane was used in
7.1 % of studies, pentobarbital in 1.6 %, and chloral hydrate,
propofol and α-chloralose were used in one study each. Ke-
tamine was used in two studies, each time in combination with
a different drug—either xylazine or meditomidine. One study
reported the combined use of urethane and α-chloralose.
Anaesthetic regime for data collection and ventilatory gas
mixtures
Twelve studies (9.5 %) changed the type of anaesthetic agent
for maintenance after initial induction, of which eight studies
(6.3 %) used alpha-chloralose (which is unsuitable for induc-
tion), two used pentobarbital (1.6 %), and individual studies
used propofol (0.8 %) or medetomidine (0.8 %). The majority
of studies continued with isoflurane (43.7 %) for maintenance,
closely followed by halothane (33.3 %; Fig. 2). In total, α-
chloralose was used in 7.1 % of studies, pentobarbital in
3.2 %, propofolin in 1.6 % and chloral hydrate in one study
(0.8 %). One study used a meditomidine/xylazine mixture for
maintenance. Studies using urethane alone (7.1 %), urethane
in combination with α-chloralose (0.8 %) or a xylazine/
Fig. 1 Choice of anaesthetic agent for induction, by percentage of studies
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ketamine mixture (0.8 %) require only a single dose of anaes-
thetic for both induction and maintenance.
We then explored the anaesthetic and ventilatory gas mix-
tures for the isoflurane and halothane groups in more detail.
Dosage data were counted in 0.1 % bins, grouped in 0.2 %
bins for plotting in Fig. 3. Because many studies specified a
dosage range rather than a fixed value, for the purposes of
constructing the histograms in Fig. 3a, c, we calculated a
weighted count, whereby the unitary contribution of a single
study was divided by the number of 0.1% bins in the specified
range. For example, a study specifying 1.0–1.2 % would con-
tribute 0.5 to both of the 1.0≤x<1.1 and 1.1≤x<1.2 % bins.
Within the isoflurane group, maintenance doses ranged from
0.8 to 3 %, with the modal dosage at ~1.4 % (Fig. 3a). Addi-
tional gases complementing isoflurane also varied between
studies (Fig. 3b), with an N2O/O2 regime with different con-
centrations applied in 34.5 % of isoflurane studies.
Similarly, halothane dosage varied between studies with a
range from 0.7 to 2 % (Fig. 3c). The modal dosage was 0.8 %,
with these studies originating from the same group of authors.
Figure 3d illustrates the differences in ventilatory gas regimes
for halothane, with the modal choice being N2/O2 (70:30 %).
Alpha-chloralose doses ranged from 50 to 80 mg/kg for
initial bolus injection, and continuous administration ranged
from 26.7 to 40 mg/kg/h. For urethane, a dose of 1.2 g/kg was
chosen in seven out of nine studies, three of which applied
additional gases (30 % O2/air). The remaining two reported a
slightly higher dose of 1.75 g/kg. In the four cases of pento-
barbital anaesthesia, two reported a 37.5-mg/kg/h dose with
additional gases (N2/O2 at 1:1), one for 10 mg/kg/h and one
Fig. 2 Choice of anaesthetic agent during maintenance, by percentage of
studies
Fig. 3 Gaseous anaesthetic doses and ventilator gas mixtures: a variation
in concentration within the isoflurane group, b variation in mixture of
ventilatory gases within the isoflurane group, c variation in concentration
within the halothane group, d variation in mixture of ventilatory gases
within the halothane group. For a and c, the bin width of specified
concentrations was 0.2 %, with bin centres denoted on the x-axis (e.g.
0.8 % corresponds to concentrations 0.7≤x<0.9 %). For b and c, very
similar specified gas mixtures, such as a “70:30 N2O/O2 mix” and “N2O/
O2 in a 2:1 ratio” were grouped together
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for 40 mg/kg. Two studies used propofol, with doses of 60 or
35 mg/kg/h and mechanical ventilation with oxygen-enriched
air (in a mechanically ventilated mix 7:1 air/O2 or 1:1 air/O2,
respectively). Each of the following anaesthetics were used in
only one study: chloral hydrate 500 mg/kg, then 150 mg/kg;
ketamine 0.1 ml/10 g of 2.5 % xylazine and 15 % ketamine in
82.5 % PBS at 0.1 ml/10 g/h; mixed 1 g/kg urethane with
65 mg/kg alpha-chloralose; mixed 1 mg/kg medetomidine
with 75 mg/kg ketamine.
Overall, the combinations of anaesthetic types, doses and
ventilatory gases used meant that across our sample of 126
studies, the largest ‘group size’ of studies using identical or
very similar methodologywas 18, of which 17 studies included
the same authors. In total, there were 73 different anaesthetic/
ventilatory gas regimes reported over the 126 studies.
Ventilation and respiration protocol
Mechanical ventilation was performed in 52.4 % of studies,
while 45.2 % did not artificially control animals’ respiratory
rates. In three studies (2.4 %), only a subset of animals was
artificially ventilated. Of those studies where animals were not
artificially ventilated, 54.4 % monitored respiration rates.
Additional monitoring
Blood gas parameters were measured in 62.7 % of studies,
while the remaining 37.3 % did not report recordings. Body
temperature was reported as being monitored and controlled
in 91.3 % of studies. Approximately two thirds of reviewed
studies recorded at least one cardiovascular parameter in the
form of heart rate and/or BP, whilst the remaining third did not
report any such measurements. Moreover, 56.3 % of studies
reported recording blood pressure, and 33.3 % of studies re-
ported recording heart rate during data collection.
fMRI method
BOLD was the most commonly used phMRI measure, being
used alone in 51.6 % of studies or in combination with other
techniques in 6.3 % of studies. rCBVmeasures alone accounted
for 36.5 % of studies and in combination with other measures
accounted for 6.3 % of studies; 4.8 % of studies measured CBF
in isolation, and it was used in combination with other measures
in 2.4 % of studies. Studies using combined techniques
accounted for 7.1 % of the total number of studies.
Discussion
The present review of preclinical phMRI methodologies re-
vealed that anaesthetic regimes and related methodology vary
substantially between laboratories, with roughly half as many
differing approaches as there were research studies in our
sample. A range of anaesthetics have been used for both in-
duction and maintenance purposes, most notably the volatile
agents isoflurane and halothane. Choice of dosage levels as
well as the mixture of ventilatory gases also differed between
as well as within research groups administering the same an-
aesthetic. Studies employing very similar or identical anaes-
thetic regimes tended to originate from the same laboratories.
With respect to physiological monitoring, studies generally
reported on such parameters, but variation existed with respect
to the type of recorded parameter, and cardiovascular mea-
surements in particular were not always reported. Lastly,
roughly half of the reviewed studies used BOLD contrast
fMRI, followed by CBV weighted imaging, and a minority
performed CBF measurements.
The major effects of the main anaesthetic types reported
upon neurotransmitter systems as well as cerebrovascular
and systemic effects are summarised in Table 1. Since evi-
dence suggests that phMRI data are likely to be affected by
the choice of anaesthetic regime due to differential actions of
anaesthetic agents (Gordon et al. 1995; Gozzi et al. 2008; Du
et al. 2009; Liu et al. 2012; Hodkinson et al. 2012), the appar-
ent laboratory dependence of these important aspects of re-
search methodology is a major concern. Specifically, interpre-
tation of the neurotransmitter effects of a drug under investi-
gation should consider likely interactions with neurotransmit-
ter effects of the anaesthetic (Table 1), especially when com-
paring between different studies. Anecdotally, it seems as
though many laboratories (our own included) establish and
then stick to an animal preparation that works well in their
hands for their particular application: this view appears to be
supported by the present findings. For fMRI studies, alpha-
chloralose is often described as one of the most effective an-
aesthetic agents due to its minimal effects on basal physiology
(Ueki et al. 1992; Lindauer et al. 1993; Nakao et al. 2001;
Austin et al. 2005); however, both isoflurane and halothane
were the most common choices for the phMRI literature
reviewed here, possibly due to the ease of induction, level of
control, fast recovery rates (Sakai et al. 2005) and the advan-
tage of reduced adverse effects for animals that are recovered
for chronic experimental designs. However, these volatile
agents, particularly halothane, are known for their
vasodilatory properties, resulting in increased baseline CBF.
Given that most neuroimaging signals used in phMRI de-
scribe changes relative to baseline, this may result in smaller
activation-evoked changes compared to anaesthetics with
lesser effects on CBF. To illustrate, Du et al. (2009) found
CBF increases in response to cocaine under alpha-chloralose,
but CBF reductions under isoflurane. This is consistent with
the minimal effects of alpha-chloralose on CBF, thereby
retaining CBF values close to basal state and facilitating a
relative increase of CBF by cocaine, whilst a higher baseline
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CBF under isoflurane may has confounded drug effects. A
greater reduction of cerebral metabolic rate of oxygen
(CMRO2), a factor in BOLD contrast phMRI, has also been
found, even more so for isoflurane compared to halothane
regimes (Todd and Drummond 1984). The known effects of
these agents in relation to neurovascular coupling and the
interpretation of phMRI data may make experimentally deter-
mined drug effects difficult to generalise and synthesise across
laboratories and studies.
In addition to the inherent vasodilatory properties of some
anaesthetics, neurovascular effects are concentration depen-
dent (Eger 1984; Maekawa et al. 1986; Abo et al. 2004;
Masamoto et al. 2009) and region dependent (Farber et al.
1997; Hendrich et al. 2001; Sicard et al. 2003; Thomas et al.
2014). Our results show that levels of isoflurane and halothane
used ranged from 0.8 to 3 % and 0.7 to 2 %, respectively. To
some extent, variation in the dose of gaseous (and indeed
other) anaesthetic agents may be expected to modulate the
magnitude of the principal effects summarised in Table 1, with
such modulations likely to be non-linear in nature. Even
though small differences are not expected to induce large
physiological variability, the above values vary greatly in
range and are likely to result in very different physiological,
neurophysiological and neurovascular effects, again compli-
cating data comparisons between laboratories. Greater resting
CBF has been linked to increasing levels of isoflurane
(Cucchiara et al. 1974; Masamoto et al. 2009), as seen by a
dose-dependent CBF increase in response to single-pulse
stimulation for isoflurane levels between 1.1 and 2.1 %
(Masamoto et al. 2009). Given the present range in isoflurane
levels for maintenance anaesthesia, these variations in dosage
may differentially affect neuroimaging results. Schummers
et al. (2008) also found that isoflurane concentrations (0.6–
1.5 %) dose-dependently reduced responses of astrocytes,
whilst neuronal sensitivity was significantly less affected.
Given accumulating evidence for the central role of astrocytes
in neurovascular coupling (Haydon and Carmignoto 2006;
Carmignoto and Gómez-Gonzalo 2010; Figley and Stroman
2011), the mechanism underpinning BOLD fMRI, decreased
sensitivity of involved astrocytes as a result of dosage varia-
tions could hence affect phMRI data. Further, while isoflurane
uniformly increases global CBF, regional CBF is found to be
heterogeneous, with less vasodilatory effects in cortical areas
relative to subcortical structures (Manohar and Parks 1984;
Farber et al. 1997; Li et al. 2013). This again poses a difficulty
in inferring upon true drug effects from (typically) whole-
brain phMRI data since responses evoked by pharmacological
challengemay depend on a three-way interaction of anaesthet-
ic protocol, brain region and administered drug.
phMRI studies also differed substantially in terms of the
composition of ventilated breathing gases, with a common
combination being oxygen (O2) and nitrous oxide (N2O). Rel-
atively few studies have investigated the impact of differing
inspired gas compositions (of the type found in this study)
upon neuronal, neurovascular or haemodynamic processes.
For instance, although the effects of hypercapnia and hypoxia
have been explored in some depth, little research has been
conducted on how normal or supra-normal concentrations of
oxygen, or the use of nitrogen vs nitrous oxide, affect these
systems in the context of neuroimaging. Sicard and Duong
(2005) manipulated inspired O2 (and CO2) concentrations un-
der isoflurane anaesthesia and found both physiological pa-
rameters and relative, i.e. baseline dependent, fMRI responses
to electric forepaw stimulation to differ significantly between
conditions. Specifically, supranormal inhaled O2 concentra-
tions (100 %) altered heart rate, blood O2 and CO2 concentra-
tions and pH and increased baseline CBF and BOLD signals.
Breathing gases have also been found to have agent-specific
neurophysiological effects. For instance, no significant differ-
ence in CBF was found between 1.0 MAC halothane alone
compared to 0.5MAC halothane with 0.5MAC nitrous oxide;
however, CBF greatly increased with 0.5 MAC isoflurane
with nitrous oxide compared to 1.0 MAC of isoflurane only
(Hansen et al. 1989). This suggests that ventilatory gases po-
tentially give rise to differential responses to pharmacological
challenges when relative fMRI measures are used. Notwith-
standing this, where laboratories optimise their ventilatory
gases in order to achieve a stable set of (systemic) physiolog-
ical parameter values, it is likely that the effects of these dif-
ferences are minimised and may to some extent usefully mit-
igate against the differing physiological effects of different
anaesthetic agents and concentrations.
Other factors which may affect relative fMRI measure-
ments are physiological parameters such as body temperature,
respiration and heart rate, blood pressure and blood gas pa-
rameters (see Steward et al. 2005). Our results have shown
that not all studies have fully reported on these physiological
factors despite their potential role in altering imaging results
indirectly. We acknowledge the possibility that studies may
not have reported on a physiological parameter despite having
monitored it (e.g. body temperature), although future studies
should aim to explicitly describe animals’ physiological
states. Briefly, body temperature can affect fMRI data by
changes in oxygen and glucose metabolism if not kept in
normal range (Carlsson et al. 1976; McCulloch et al. 1982),
and so animals need to be homeothermically maintained.
Blood gases should be recorded and respiration rate controlled
by mechanical ventilation or at least monitored to enable con-
trol for hyper/hypoventilating animals. Heart rate and/or BP
should also be continuously recorded since systemic drug ef-
fects can arise in terms of cardiovascular changes, as demon-
strated by studies administering noradrenaline to induce blood
pressure changes which ultimately result in imaging findings
which differ from control conditions (Wang et al. 2006; Gozzi
et al. 2007). Blood pressure in particular is a useful physio-
logical measure since analysis techniques can correct for
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cardiovascular effects by modelling the known BP changes
and how these may affect brain haemodynamics as a covari-
ate. In addition, the recording of heart rate and respiration rate
will assist subsequent research groups in more precisely
matching the physiology, including anaesthetic depth, of their
animals to previous experiments in order to facilitate compar-
ison of data. However, our review revealed that approximately
one third of studies did not monitor cardiovascular
parameters.
Other differences between animal models in terms of sub-
ject sex, age/weight, strain or species are also important to
consider. Although these concerns are ubiquitous in in vivo
neuroscience research, they may interact with some of the
specific phMRI issues raised here. For instance, oestrous cy-
cles in female rodents have been shown to influence fMRI
BOLD signalling (Dietrich et al. 2001), whilst age and asso-
ciated brain development (which has separate neuronal,
vascular and neurovascular trajectories; Harris et al. 2011)
may be a critical factor to control for in investigations of a
wide range of drug actions. It is therefore important that pa-
rameters such as strain and sex are at the very least reported,
yet in our sample 12.7 % of studies did not report animal sex
and 4.0 % of studies did not report animal strain. Weight,
rather than age, was reported in 68.3 % of studies, while
17.5 % of studies gave no indication of animal developmental
level. Variability in species or strains used, whilst an addition-
al source of complexity, does however offer some advantage
in terms of improving robustness and confidence in research
findings that are consistent across different animal models.
Indeed the same may be said of inconsistencies in other as-
pects of methodology such as anaesthetic regime. A compre-
hensive description of methodology, including subject details,
is key to translating the potential challenges in methodological
variability into sources of additional confidence in research
observations.
The studies reviewed utilised a range of MRI tech-
niques in order to obtain functional maps associated with
drug treatment, including BOLD, CBV and CBF weighted
pulse sequences. Which of these approaches are most ap-
propriate given the issues outlined above? Although half
of the studies reported utilised BOLD imaging, it has a
number of limitations. Firstly, the BOLD signal reflects
composite changes in CBV and oxygenation that are in
turn driven by metabolism and CBF changes, with the
latter arising most directly from neurovascular signalling
(Martin 2014). The BOLD contrast mechanism thus has
additional points of susceptibility to anaesthetic or meth-
odological factors relative to some other neuroimaging
modalities. Secondly, BOLD signals provide qualitative
rather than quantitative measures of underlying haemody-
namic changes, with signals expressed as a percentage
change relative to an essentially arbitrary baseline value.
Thus, comparisons between studies where haemodynamic
baseline parameters may be altered are difficult. For in-
stance, it is not possible to determine whether a reduction
in BOLD signalling is due to a reduced drug action or to
an elevated baseline BOLD signal upon which equivalent
(percentage) increases are limited due to non-linearities in
haemodynamic responding (Vazquez et al. 2006).
Perfusion-based imaging techniques such as arterial spin
labelling, which determines cerebral blood flow changes
by measuring the progression of ‘magnetically tagged’
blood, as well as contrast-enhanced CBV weighted imag-
ing (which uses an exogenous contrast agent to enhance
signals from blood), are able to provide quantitative mea-
surement of cerebral blood flow and volume changes, re-
spectively. These were employed in a number of the stud-
ies reviewed here. Such measures greatly facilitate com-
parisons between studies, subjects, brain regions, drug or
anaesthetic conditions. By combining BOLD imaging
with concurrent CBF and/or CBV data acquisition, it is
also possible to calculate additional parameters such as
the cerebral metabolic rate of oxygen (e.g. see Luo et al.
2009). A more comprehensive measurement of the hae-
modynamic response simultaneously improves the charac-
terisation of drug effects and possibilities for differentiat-
ing these effects from the physiological impact of meth-
odological factors which we show here to vary consider-
ably between studies.
The present review raises awareness for future fMRI-based
pharmacological studies. We have highlighted some issues
related to the effects of anaesthetics on the basal physiological
state of the animal, which could ultimately bias the interpre-
tations of the drug effects under investigation. Differences in
anaesthetic regimes combined with unknown interactions be-
tween applied anaesthetics and investigated drug complicate
comparisons on pharmacological effects. This also has impli-
cations for relating findings from animal studies to those from
human phMRI: in contrast to rodent neuroimaging, partici-
pants are not usually anaesthetised, resulting in major differ-
ences in physiological state for each species given the
neuromodulatory effects of anaesthetics (e.g. Deakin et al.
2008; see Anderson et al. 2008). Anaesthetic effects thus po-
tentially confound translational predictions for human phMRI,
exacerbating the already complex issue of species differences
(Markou et al. 2009).
The choice of anaesthetic regime depends on several fac-
tors, thus ruling out a single protocol for phMRI studies. It is
desirable to employ an anaesthetic which minimally affects
basal physiology; however, the neurotransmitter system
targeted by the drug under investigation as well as by the
anaesthetic also needs to be considered, primarily to avoid
actions on the same system which are known a priori. For
instance, a drug modulating GABAergic neurotransmission
(e.g. anti-epileptic drugs, Treiman 2001; Madsen et al. 2009)
may compete with the typical GABAergic actions of some
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anaesthetics, thereby potentially confounding the insights into
drug action. Route and time course of administration is also an
important consideration: most of the studies reported here uti-
lise an inhalational agent with either intravenous or intraperi-
toneal administration of the drug under investigation. It is
important to consider the potential differences in pharmaco-
dynamics and effective time course (including stability) of
anaesthetic action and how this could interact with equivalent
parameters for action of the drug under investigation. Gaseous
anaesthetics such isoflurane and some injectables are rapidly
metabolised compared to urethane where a single injection
can give stable anaesthesia for >10 h. Although the former
agents require constant infusion, providing an advantage for
rapid modulation of anaesthetic depth, accumulation of the
agent in the body (especially in the fat) can produce variations
in effective anaesthetic dose over time. This can be an impor-
tant consideration in phMRI, where this may produce signal
changes occurring over the same time frequency domain as
those produced by the drug under investigation. Separating
slow oscillations in signals arising due to anaesthetic admin-
istration, drug action or indeed non-physiological sources
such as hardware noise can be a challenging component of
data analysis. Control experiments are therefore critical to
determine the extent of non-drug signal changes, and in some
cases, it may be desirable to conduct pilot phMRI experiments
under different anaesthetic regimes before choosing the appro-
priate type and level of agent (e.g. Asanuma et al. 2008).
Another method which currently receives increased at-
tention due to its advantage of avoiding confounding an-
aesthetic effects is the development of awake animal
models for neuroimaging studies (e.g. Skoubis et al.
2006; Chin et al. 2008; Ferris et al. 2011; Brydges et al.
2013; Martin et al. 2013). Data from these approaches are
potentially much more readily translatable human re-
search, where anaesthetics are rarely employed for phMRI
studies, as well as to the field of behavioural (neuro)phar-
macology. In these approaches, it is however important to
avoid substituting the deleterious effects of anaesthesia
with alternate complexities introduced by stress where
animals are restrained (and due to the acoustic noise of
the MRI environment). Although habituating or condi-
tioning animals to tolerate forms of immobilisation to en-
able imaging is possible, careful monitoring of additional
physiological parameters is also important in order to as-
certain the effectiveneness of this approach and to ensure
that a state of ‘learned helplessness’ has not been induced
by the habituation procedures (e.g. see Reed et al. 2013).
Given the well-established effects of stress and restraint
stress in particular (itself a model for inducing depression
in rodents), consideration of these factors is critical in the
phMRI context, where interactions of (for example) acti-
vation of the hypothalamic adrenal axis with drug chal-
lenges may confound data interpretation. Interestingly, a
recent study by Scott et al. (2013) describes a promising
approach whereby rats are trained by operant conditioning
to voluntarily accept head immobilisation for neuroimag-
ing (albeit in a microscopy rather than MR imaging envi-
ronment). Such approaches, which may be facilitated by
developing preclinical MR environments optimised for
work in conscious animals, may represent an important
route for future development.
This review reveals the extent of variation in research
methodologies used for rodent phMRI studies, showing dif-
ferences not only in choice of anaesthetic agents but, impor-
tantly, also in associated dosage levels as well as variations in
type and concentration of additional ventilatory gases and
physiological monitoring and regulation. To conclude, we
make a series of recommendations, based on the findings of
this review, for the design and reporting of future preclinical
phMRI studies:
1. The anaesthetic regime should be actively chosen primar-
ily on the basis of two criteria: (a) how to minimise pos-
sible drug–anaesthetic interactions; (b) facilitation of crit-
ical comparisons or synthesis with previous research find-
ings. Authors should provide a brief rationale for choos-
ing a specific anaesthetic regime and consider the impact
of this choice on the specific research findings.
2. Physiological parameters, including as a minimum heart
and respiration rate, blood gases (O2 and CO2) and, where
possible, blood pressure measurements, should always be
provided. This will allow (a) a fuller appreciation of phys-
iological drug effects and (b) standardisation of physio-
logical status between differing anaesthetic regimes/
laboratories.
3. Studies should attempt to provide an indication of anaes-
thetic depth via any available physiological (EEG, ECG)
or other (e.g. reflexes) indicators in order to facilitate
matching of anaesthetic depth between laboratories and
methodological approaches.
4. Consider an additional ‘control group’ of animals or,
where possible, a repeated-measures approach, in which
either the anaesthetic dose or the anaesthetic type is al-
tered in order to elucidate the impact of these choices
upon the data acquired and improve confidence in the
main findings.
5. phMRI protocols to acquire more than one haemodynam-
ic measure (e.g. combined BOLD and CBF imaging)
should be used routinely since these can be deployed with
little cost to spatial or temporal resolution (or experimen-
tal duration) yet provide a more comprehensive assess-
ment of haemodynamic responses to drug challenge.
6. Now that methods for conducting phMRI in un-
anaesthetised animals have been developed, these should
also be given consideration when planning non-invasive
preclinical neuroimaging studies.
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